Zheng-Wang Chen1, 2, Ping Zhang1, Xue-Jun Zhang1, Yu-Xing Tong2 and Hua Jiang2
1Shan Dong Tianjiu Biotech Co. LTD, China 2Huazhong University of Science and Technology, P. R. China
Posters-Accepted Abstracts: J Diabetes Metab
We have previously reported that the bioactive peptide aglycin regulates glucose homeostasis in Type 2 diabetic (T2D) mice by the process of activating Insulin Receptor/Insulin Receptor Substrate1 Pathway (IR/IRS1 P). Furthermore, we have reported that the bioactive peptide vglycin, a homologous peptide of aglycin, normalizes fasting glucose and restores impaired pancreatic function in T2D Wistar rats. Both peptides aglycin and vglycin, consisted of 37 amino acid residues respectively and share 35 residues identically. In particular, the 6 cystines are located at the same sites and constitute the structure domain ??cystine knot? which can resist hydrolysis from proteases in the digestive tract. Recently, we have successfully conducted the toxicity tests with the peptides, aglycin and vglycin, in rats and mice respectively. We have also determined their effectiveness in 107 volunteers with Diabetes and preDiabetes. Our findings reveal that the peptides aglycin or vglycin take a crucial role in the prevention and treatment of Diabetes. We will report these results in the Diabetic Medications-2015 conference of USA.
Email: zwchen@mail.hust.edu.cn
